{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:23:57Z","timestamp":1795148637979,"version":"4.10.3"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Children with Down syndrome have an augmented risk for B-cell acute lymphoblastic leukemia (DS-ALL), which is associated with lower survival than in non-DS-ALL. It is known that cytogenetic abnormalities common in childhood ALL are less frequent in DS-ALL, while other genetic aberrancies (ie, <jats:italic toggle=\"yes\">CRLF2<\/jats:italic> overexpression and <jats:italic toggle=\"yes\">IKZF1<\/jats:italic> deletions) are increased. A possible cause for the lower survival of DS-ALL that we herewith evaluated for the first time was the incidence and prognostic value of the Philadelphia-like (Ph-like) profile and the IKZF1plus pattern. These features have been associated with poor outcome in non-DS ALL and therefore introduced in current therapeutic protocols. Forty-six out of 70 DS-ALL patients treated in Italy from 2000 to 2014 displayed Ph-like signature, mostly characterized by <jats:italic toggle=\"yes\">CRLF2<\/jats:italic> (n = 33) and <jats:italic toggle=\"yes\">IKZF1<\/jats:italic> (n = 16) alterations; only 2 cases were positive for <jats:italic toggle=\"yes\">ABL<\/jats:italic>-class or <jats:italic toggle=\"yes\">PAX5<\/jats:italic>-fusion genes. Moreover, in an Italian and German joint cohort of 134 DS-ALL patients, we observed 18% patients positive for IKZF1plus feature. Ph-like signature and <jats:italic toggle=\"yes\">IKZF1<\/jats:italic> deletion were associated with poor outcome (cumulative incidence of relapse: 27.7\u2009\u00b1\u20096.8% versus 13\u2009\u00b1\u20097%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04 and 35.2\u2009\u00b1\u20098.6% versus 17\u2009\u00b1\u20093.9%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007, respectively), which further worsens when <jats:italic toggle=\"yes\">IKZF1<\/jats:italic> deletion was co-occurring with <jats:italic toggle=\"yes\">P2RY8::CRLF2<\/jats:italic>, qualifying for the IKZF1plus definition (13\/15 patients had an event of relapse or treatment-related death). Notably, <jats:italic toggle=\"yes\">ex vivo<\/jats:italic> drug screening revealed sensitivity of IKZF1plus blasts for drugs active against Ph-like ALL such as Birinapant and histone deacetylase inhibitors. We provided data in a large setting of a rare condition (DS-ALL) supporting that these patients, not associated with other high-risk features, need tailored therapeutic strategies.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000892","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T20:01:20Z","timestamp":1685131280000},"page":"e892","source":"Crossref","is-referenced-by-count":16,"title":["Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia"],"prefix":"10.1002","volume":"7","author":[{"given":"Chiara","family":"Palmi","sequence":"first","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bresolin","sequence":"additional","affiliation":[{"name":"Women\u2019s and Children\u2019s Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy"},{"name":"Istituto di Ricerca Pediatrica-Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Junk","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Fazio","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Zaliova","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Oikonomou","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Scharov","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stanulla","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Moericke","sequence":"additional","affiliation":[{"name":"Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[{"name":"Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[{"name":"Women\u2019s and Children\u2019s Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy"},{"name":"Istituto di Ricerca Pediatrica-Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanil","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Saitta","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Galbiati","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bardini","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lo Nigro","sequence":"additional","affiliation":[{"name":"Center of Pediatric Hematology and Oncology, Azienda Policlinico-San Marco, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Conter","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Statistics, University of Milan Bicocca, Monza, Italy"},{"name":"Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[{"name":"Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"},{"name":"School of Medicine and Surgery, University of Milan Bicocca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruy","family":"te Kronnie","sequence":"additional","affiliation":[{"name":"Women\u2019s and Children\u2019s Health Department, Hematology-Oncology Clinic and Laboratory, University-Hospital of Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[{"name":"Pediatrics, Christian-Albrechts-University and University Medical Center Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy"},{"name":"Medical Genetics, School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"R1-20231116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.20242","article-title":"Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment.","volume":"44","author":"Ravindranath","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20231116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"R3-20231116","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"key":"R4-20231116","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"R5-20231116","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/leu.2012.84","article-title":"Outcome in children with Down\u2019s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.","volume":"26","author":"Buitenkamp","year":"2012","journal-title":"Leukemia"},{"key":"R6-20231116","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1038\/ncomms5654","article-title":"Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.","volume":"5","author":"Nikolaev","year":"2014","journal-title":"Nat Commun"},{"key":"R7-20231116","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1111\/cas.14160","article-title":"Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome.","volume":"110","author":"Kubota","year":"2019","journal-title":"Cancer Sci"},{"key":"R8-20231116","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/ijms21062193","article-title":"The current genomic and molecular landscape of Philadelphia-like acute lymphoblastic leukemia.","volume":"21","author":"Shiraz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R9-20231116","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/s41375-020-0854-5","article-title":"Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.","volume":"34","author":"Laurent","year":"2020","journal-title":"Leukemia"},{"key":"R10-20231116","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia.","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"key":"R11-20231116","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"R12-20231116","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"R13-20231116","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"key":"R14-20231116","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.","volume":"105","author":"Cario","year":"2020","journal-title":"Haematologica"},{"key":"R15-20231116","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2008-10-187203","article-title":"Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.","volume":"114","author":"Mills","year":"2009","journal-title":"Blood"},{"key":"R16-20231116","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","article-title":"Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.","volume":"28","author":"Haferlach","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-20231116","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Global approach to the diagnosis of leukemia using gene expression profiling.","volume":"106","author":"Haferlach","year":"2005","journal-title":"Blood"},{"key":"R18-20231116","doi-asserted-by":"crossref","first-page":"104224","DOI":"10.1016\/j.ebiom.2022.104224","article-title":"PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.","volume":"83","author":"Fazio","year":"2022","journal-title":"EBioMedicine"},{"key":"R19-20231116","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/leu.2012.101","article-title":"Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.","volume":"26","author":"Palmi","year":"2012","journal-title":"Leukemia"},{"key":"R20-20231116","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.3324\/haematol.2014.114447","article-title":"Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.","volume":"100","author":"Bugarin","year":"2015","journal-title":"Haematologica"},{"key":"R21-20231116","doi-asserted-by":"crossref","first-page":"59260","DOI":"10.18632\/oncotarget.10610","article-title":"CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.","volume":"7","author":"Palmi","year":"2016","journal-title":"Oncotarget"},{"key":"R22-20231116","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jmoldx.2017.05.004","article-title":"Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia.","volume":"19","author":"Benard-Slagter","year":"2017","journal-title":"J Mol Diagn"},{"key":"R23-20231116","doi-asserted-by":"crossref","first-page":"42398","DOI":"10.18632\/oncotarget.16392","article-title":"High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.","volume":"8","author":"Vendramini","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20231116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"R25-20231116","doi-asserted-by":"crossref","first-page":"13768","DOI":"10.1073\/pnas.1606220113","article-title":"Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers.","volume":"113","author":"Alaei-Mahabadi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-20231116","first-page":"4666","article-title":"The paired box domain gene PAX5 is fused to ETV6\/TEL in an acute lymphoblastic leukemia case.","volume":"61","author":"Cazzaniga","year":"2001","journal-title":"Cancer Res"},{"key":"R27-20231116","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children\u2019s Oncology Group.","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"R28-20231116","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/0008-5472.CAN-16-0523","article-title":"Acute Sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant.","volume":"76","author":"Richmond","year":"2016","journal-title":"Cancer Res"},{"key":"R29-20231116","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/leu.2017.93","article-title":"The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.","volume":"31","author":"Savino","year":"2017","journal-title":"Leukemia"},{"key":"R30-20231116","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"R31-20231116","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pbc.22686","article-title":"TEL\/AML1-positive patients lacking TEL exon 5 resemble canonical TEL\/AML1 cases.","volume":"56","author":"Zaliova","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R32-20231116","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3026(21)00272-6","article-title":"Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.","volume":"8","author":"Michels","year":"2021","journal-title":"Lancet Haematol"},{"key":"R33-20231116","doi-asserted-by":"crossref","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","article-title":"Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.","volume":"114","author":"Schwartzman","year":"2017","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:06:41Z","timestamp":1702922801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000892","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}